

Chondros Dimitrios  
 Form 3  
 May 07, 2018

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Chondros Dimitrios</p> <p>(Last) (First) (Middle)</p> <p>C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY ROAD</p> <p>(Street)</p> <p>SAN DIEGO, CA 92121</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>05/02/2018</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>HALOZYME THERAPEUTICS INC [HALO]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner  <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other                  (give title below) (specify below)                  SVP, Chief Medical Officer</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person  <input type="checkbox"/> Form filed by More than One Reporting Person</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	34,076 <sup>(1)</sup>	D	À

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
-----------------------------------------------	-------------------------------------------------------------	------------------------------------------------------------------	---------------------------	----------------------	--------------------------------------------

## Edgar Filing: Chondros Dimitrios - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Option to Purchase Common Stock	08/03/2016 <sup>(2)</sup>	08/03/2025	Common Stock	100,000	\$ 23.03	D	Â
Option to Purchase Common Stock	02/03/2017 <sup>(2)</sup>	02/03/2026	Common Stock	41,841	\$ 8.11	D	Â
Option to Purchase Common Stock	02/22/2018 <sup>(2)</sup>	02/22/2027	Common Stock	24,861	\$ 12.07	D	Â
Option to Purchase Common Stock	06/01/2018 <sup>(3)</sup>	06/01/2027	Common Stock	13,218	\$ 12.24	D	Â
Option to Purchase Common Stock	02/14/2019 <sup>(3)</sup>	02/14/2028	Common Stock	47,635	\$ 18.41	D	Â
Restricted Stock Units	02/22/2018 <sup>(4)</sup>	Â <sup>(4)</sup>	Common Stock	11,651	\$ <sup>(4)</sup>	D	Â
Restricted Stock Units	02/14/2019 <sup>(5)</sup>	Â <sup>(5)</sup>	Common Stock	8,170	\$ <sup>(5)</sup>	D	Â
Restricted Stock Units	02/14/2019 <sup>(5)</sup>	Â <sup>(5)</sup>	Common Stock	27,160	\$ <sup>(5)</sup>	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Chondros Dimitrios C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121	Â	Â	Â SVP, Chief Medical Officer	Â

## Signatures

/s/ James R. Oehler as attorney-in-fact for Dimitrios Chondros 05/07/2018

<sup>\*\*</sup>Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 7,500 shares of restricted stock that vest in equal pro rata amounts on August 3, 2018 and August 3, 2019. Also includes 12,330 shares of restricted stock that vest in equal pro rata amounts on February 3, 2019 and February 3, 2020.
- (2) This option vested one-fourth on such date and vests 1/48th monthly thereafter.
- (3) This option vests one-fourth on such date and then 1/48th monthly thereafter.
- (4)

## Edgar Filing: Chondros Dimitrios - Form 3

This award vested one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Represents a restricted stock unit award with no exercise price.

- (5) This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Represents a restricted stock unit award with no exercise price.

Â

### Remarks:

Exhibit List: Â Â Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.